Navigation Links
United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Date:2/15/2011

al measure as it excludes certain operating expenses that are recurring in nature. Furthermore, our calculation of this non-GAAP financial measure may differ from the methodology used by other companies. The presentation of this non-GAAP financial measure should not to be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. A reconciliation of net income, the most directly comparable GAAP financial measure, to earnings before non-cash charges can be found in the table above under the heading, Earnings before Non-Cash Charges.

Forward-looking StatementsStatements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations about operating results and demand for our products, and our expected timing of enrollment and unblinding of our FREEDOM-M and FREEDOM-C2 clinical trials. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.  Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 15, 2011, and assume no obligation to update or revise the information contained in this press release whether as a result of new informa
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
5. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
6. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
7. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
8. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
9. United Therapeutics Reports Third Quarter 2008 Financial Results
10. Lilly Contributes $11.1 Million to United Way Annual Campaign
11. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 GEA Niro ... table top laboratory homogenizer, the PandaPLUS 2000, which is ... nanoemulsions , and cell disruption . This compact ... products, fruit juices, liquid food, food additives and ingredients ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions ... a record-breaking year across the board for the company. ... Platform and our Smart Data solutions, our customers were able ... led to record growth for the company in 2014,” said ...
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Cambridge Semantics Announces Record Results for 2014 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... fields to drive iron-bearing nanoparticles to metal stents in ... payload that successfully prevents blockages in those vessels. In ... at a lower dose than conventional non-magnetic stent therapy. ... is the latest in a series of studies at ...
... ... and xenograft response prediction. MM-111 breast cancer study in combination with trastuzumab. , ... Cambridge, MA (PRWEB) April ... on MM-121 and MM-111, the two lead candidates in the company’s pipeline of five ...
... Doctors could soon be prescribing a dose of dark ... from dangerously high blood pressure in their abdomen, according ... Liver CongressTM 2010, the Annual Meeting of the European ... According to the Spanish research, eating dark chocolate ...
Cached Biology Technology:Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 2Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 3Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 4Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR) 2Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR) 3Study shows potential benefit of dark chocolate for liver disease patients 2
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... technology and tech stocks, releases video from the CES 2015 ... security consultant Apollo Robbins . Apollo shows ... Wocket™ biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... of cancer, including stomach, liver and colon, are far more ... that differences in lifestyle, such as diet and smoking, may ... differences are rooted in basic biological differences between men and ... MIT shows that treating male mice with estrogen dramatically lowers ...
... giant seaweeds, are spreading fast, with harmful effects on ... the Mediterranean seabed. Some native species, such as sea ... invasion, but only during its early stages, or when ... carried out a study to look at the ability ...
... salmon were to escape from captivity they could succeed ... Canadian researchers have found. Their research, published in ... GM salmon as they are considered for commercial farming. ... long been of interest to the aquaculture industry and ...
Cached Biology News:Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3Sea urchins cannot control invasive seaweeds 2First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: